Skip to main content
someone in lab using a multi pippitte

2 years ago

UNC-Chapel Hill receives $65M from NIH for antiviral drug development center

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health awarded the UNC Gillings School of Global Public Health a $65 million grant establishing an Antiviral Drug Discovery Center to develop oral antivirals that can combat pandemic-level viruses like COVID-19. The center builds upon and is tightly affiliated with UNC’s Rapidly Emerging Antiviral Drug Development Initiative. The READDI-AViDD Center, one of nine established by the NIH, is an integrated public-private partnership with a renowned, interdisciplinary research team of experts from the Gillings School, UNC School of Medicine and UNC Eshelman School of Pharmacy. They will apply cutting-edge technologies to develop oral therapies that target viral families with high potential to cause a pandemic in the future.